BAMCO Inc’s Jasper Therapeutics JSPR Stock Holding History

BAMCO Inc’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-20,000	Closed	-$454K	–	335
2024 Q2	$454K	Buy	+20,000	New	+$480K	﹤0.01%	316

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BAMCO Inc's JSPR Position: Q3 2024 in Review

BAMCO Inc sold out of Jasper Therapeutics (JSPR) in Q3 2024, closing a stake of 20,000 shares — an estimated $454K sold.

BAMCO Inc first reported a position in JSPR in Q2 2024 and held it in 1 quarter. The position peaked at $454K in Q2 2024. 81 funds tracked by Wall St. Rank hold JSPR as of Q3 2024.

BAMCO Inc reported no remaining Jasper Therapeutics position as of Q3 2024 after selling out during the quarter.
BAMCO Inc sold 20,000 Jasper Therapeutics shares in Q3 2024, an estimated $454K.
BAMCO Inc first reported a position in Jasper Therapeutics in Q2 2024 and held it in 1 quarter.
BAMCO Inc's Jasper Therapeutics position peaked at $454K in Q2 2024.
81 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2024.

Based on BAMCO Inc's 13F filing for Q3 2024, filed 14 Nov 2024.